Two Sigma Advisers
NRIX icon

Two Sigma Advisers’s Nurix Therapeutics NRIX Stock Holding History

Two Sigma Advisers’s Portfolio NRIX Stock Details NRIX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		– Sell
-174,700
Closed -$1.61M – 2535
2025
Q3 		$1.61M Sell
174,700
-109,900
-39% -$1.14M ﹤0.01% 1230
2025
Q2 		$3.24M Buy
284,600
+89,200
+46% +$964K 0.01% 907
2025
Q1 		$2.32M Buy
195,400
+116,300
+147% +$1.95M 0.01% 1099
2024
Q4 		$1.49M Buy
79,100
+20,000
+34% +$458K ﹤0.01% 1265
2024
Q3 		$1.33M Sell
59,100
-30,400
-34% -$689K ﹤0.01% 1275
2024
Q2 		$1.87M Sell
89,500
-88,400
-50% -$1.38M ﹤0.01% 1230
2024
Q1 		$2.62M Buy
177,900
+148,800
+511% +$1.6M 0.01% 1083
2023
Q4 		$300K Buy
29,100
+9,900
+52% +$67.9K ﹤0.01% 2098
2023
Q3 		$151K Buy
19,200
+4,000
+26% +$36.5K ﹤0.01% 2146
2023
Q2 		$152K Buy
15,200
+3,300
+28% +$33.7K ﹤0.01% 2141
2023
Q1 		$106K Buy
+11,900
New +$124K ﹤0.01% 2375
2022
Q2 		– Sell
-12,200
Closed -$171K – 2813
2022
Q1 		$171K Buy
+12,200
New +$217K ﹤0.01% 2416

Other funds holding NRIX

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
GA
General Atlantic New York $2.15B AUM 35.02% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
VPC
Vestal Point Capital New York $3.58B AUM 189.12% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Two Sigma Advisers's NRIX Position: Q4 2025 in Review

Two Sigma Advisers sold out of Nurix Therapeutics (NRIX) in Q4 2025, closing a stake of 174,700 shares — an estimated $1.61M sold.

Two Sigma Advisers first reported a position in NRIX in Q1 2022 and held it in 12 quarters. The position peaked at $3.24M in Q2 2025. 182 funds tracked by Wall St. Rank hold NRIX as of Q4 2025.

  • Two Sigma Advisers reported no remaining Nurix Therapeutics position as of Q4 2025 after selling out during the quarter.
  • Two Sigma Advisers sold 174,700 Nurix Therapeutics shares in Q4 2025, an estimated $1.61M.
  • Two Sigma Advisers first reported a position in Nurix Therapeutics in Q1 2022 and held it in 12 quarters.
  • Two Sigma Advisers's Nurix Therapeutics position peaked at $3.24M in Q2 2025.
  • 182 funds tracked by Wall St. Rank held Nurix Therapeutics as of Q4 2025.

Based on Two Sigma Advisers's 13F filing for Q4 2025, filed 17 Feb 2026.